Copyright © 2016 Korean Neurological Association 147 Helicobacter pylori (HP) is a common infection of the gastrointestinal system that is usually related to peptic ulcers. However, recent studies have revealed relationships between HP and many other diseases. Although the exact mechanism is unknown, HP can prevent the ab- sorption of certain drugs. A high prevalence of HP has been found in patients with Parkin- son’s disease, and this bacterium causes motor fluctuations by affecting the absorption of le- vodopa, which is the main drug used to treat Parkinson’s disease. Eradicating HP from patients with Parkinson’s disease by applying antibiotic treatment will increase the absorption of le- vodopa and decrease their motor fluctuations.
Key Wordszz Parkinson’s disease, Helicobacter pylori, levodopa, motor fluctuations.
Association between Parkinson’s Disease and Helicobacter Pylori
INTRODUCTION
Parkinson’s disease (PD) was first described by James Parkinson in 1817 with the name of
‘shaking palsy’.1 PD is a progressive neurodegenerative disease that occurs due to the loss of dopaminergic neurons in the substantia nigra pars compacta. PD is a complex and mul- tisystem disease of unknown etiology.2 However, recent studies have found that infection plays a role in the etiology of PD, such as by bacterial overgrowth and involving cytomega- lovirus, Epstein Barr virus, herpes simplex virus type-1 and Helicobacter pylori (HP) in the small intestine.3,4 The most-common symptoms are related to the motor system (bradyki- nesia/hypokinesia, rigidity, tremor and postural abnormality), with also non-motor symp- toms such as constipation, pain, genitourinary problems, sleep disorders, depression, auto- nomic dysfunction, cognitive abnormalities, dementia and gastrointestinal dysfunction.2,5-7
HELICOBACTER PYLORI
HP is a Gram-negative bacterium found on the luminal surface of the gastric epithelium, and it was first isolated by Warren and Marshall8 in 1983. HP induces chronic inflammation of the underlying mucosa, with the infection usually being contracted in the first years of life and tending to persist indefinitely unless treated.8 It was initially found to cause gas- tritis, peptic ulcer and gastric cancer. However, subsequent studies have revealed that it is also related to diseases of other systems such as hematological disorders (iron-deficiency anemia and idiopathic thrombocytopenic purpura),9 cardiovascular diseases (ischemic heart disease), neurological diseases (stroke, PD, and Alzheimer’s disease), obesity, and der- matological diseases.10
Gülşah C¸amcıa Sıdıka Oğuzb
a Arrhythmias Unit, Research and Application Hospital, Kocaeli University, Kocaeli, Turkey
b Internal Medicine Nursing Department, Nursing Department, Health Sciences Faculty, Marmara University, Üsküdar, Istanbul, Turkey
pISSN 1738-6586 / eISSN 2005-5013 / J Clin Neurol 2016;12(2):147-150 / http://dx.doi.org/10.3988/jcn.2016.12.2.147
Received July 13, 2015 Revised November 24, 2015 Accepted November 25, 2015 Correspondence Gülşah Camcı, MSc Arrhythmias Unit,
Research and Application Hospital, Kocaeli University,
Umuttepe Campus, Kocaeli 41380, Turkey Tel +90-507 890 79 80 Fax +90-262 303 10 33
E-mail gulsah_camci@hotmail.com
cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Com- mercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
JCN
Open Access REVIEW148 J Clin Neurol 2016;12(2):147-150
Parkinson’s Disease and Helicobacter Pylori
JCN
PREVALENCE OF HELICOBACTER PYLORI INFECTION IN THE PATIENTS
WITH PARKINSON’S DISEASE
A few studies have found the prevalence of HP infection to be high in PD patient. Dobbs et al.11 found that the urea breath test was positive in 48% of 105 PD patient. while Pier- antozzi et al.,12 Lee et al.,13 Dobbs et al.,14 and Tan et al.,15 ob- tained positive HP results in 36%, 53%, 70%, and 32% of 79, 65, 51 and of 102 PD patients, respectively (Table 1).
Several case-control studies have shown the HP antibody to be five times more common in PD patients older than 80 years.16 Another study found that positivity in an HP test was three times more common in PD patients than in a healthy control group.17
PARKINSON ’S DISEASE AND HELICOBACTER PYLORI
The relationship between PD and gastric ulcer was first re- ported in 1960. An increased prevalence of gastric ulcer in PD patients was first described as an independent compo- nent of the disease, resulting in gastrointestinal symptoms being considered one of the symptoms experienced by all PD patients. This means that gastritis as hypokinesia might also be seen in PD patients. Researchers found that there was a re- lationship between PD and HP, and that HP might actually cause PD.11,18-20
One proposed hypothesis was that HP shows a neurotoxic effect by increasing cholesterol glucosides, with HP causing PD by degenerating dopaminergic neurons in the brain.20
A second proposed hypothesis is that when HP infection is not controlled by the immune system or HP is not eradi- cated, HP causes the development of PD by damaging dopa- minergic cells in the brain.21 It was stated that HP might lead to the pathogenesis of PD by causing apoptosis of nerve cells after passing the blood-brain barrier after oral ingestion, na- sal odor inhalation, or via circulating monocytes.22
The primary pharmacological agent used in PD patients to replace dopamine is levodopa.23 HP not only causes the de-
velopment of PD but also leads to motor fluctuations in PD patients by affecting the absorption of levodopa.24 HP in- fection prevents the absorption of levodopa, thyroxine and delavirdine, with the absorption of levodopa in PD patients being observed to increase by 21–54% following HP-eradi- cation.25 HP infection is thought to affect drug absorption via its potential effects on intragastric pH.25,26
It was further found that successful eradication of HP in PD patients decreased motor fluctuations by affecting the bioavailability of levodopa. These finding together indicate the potential importance of HP eradication in PD patients.27
Lee et al.13 investigated the effects of HP on the clinical re- sponse to levodopa and whether motor fluctuations in PD patients could be decreased by HP eradication. Those au- thors investigated the presence of HP in 65 PD patients us- ing the urea breath test. HP was detected in 35 of these pa- tients, and so the response to levodopa and clinical features were compared between these two groups. The onset of the effect of levodopa, the duration of drug action (‘on-time’), and the motor movements as measured by the Unified Par- kinson’s Disease Rating Scale (UPDRS) were evaluated in both groups. There was no difference between the groups in terms of age, duration of disease, scores on the Hoehn-Yahr scale or UPDRS-III, daily dose of levodopa, or frequency of dyskinesia. In PD patients with HP infection, the onset time of levodopa was longer, and the ‘on-time’ was shorter com- pared to PD patients who did not have HP infection. These data suggest that HP prevents the absorption of levodopa in PD patient. After administering antibiotic treatment to PD patients to eradicate HP, the ‘onset’ time decreased and the ‘on-time’ increased when compared to the pretreatment values. That study concluded that motor fluctuations might be decreased in PD patients by eradicating HP.
Tan et al.15 found that 32.4% of 102 PD patients were in- fected with HP. These infected PD patients were older (age, 68.4±7.3 years, mean±SD) and exhibited worse motor func- tion (UPDRS-III score, 34.0±13.0 vs. 27.3±10.0, p=0.04;
pegboard test, 6.4±3.3 pins vs. 8.0±2.7 pins, p=0.04; and
‘timed-gait’ test, 25.1±25.4 s vs. 15.5±7.6 s, p=0.08). That study revealed important effects of HP infection on UP- DRS-III and ‘timed-gait’ tests of PD patients; it was found that HP status and its relationship with these motor results varied according to age.
Pierantozzi et al.28 applied HP eradication to 17 patients and administered a common antioxidant treatment to an- other 17 patients among 34 PD patients with HP infection.
They found that the absorption of levodopa was significantly increased in the HP-eradication group relative to the placebo group. That study found that HP affected the absorption of levodopa, which caused motor fluctuations by decreasing the Table 1. Prevalence of HP infection in patients with PD
Authors (year) PD patients (n) Prevalence of HP infection
Dobbs et al.11 (2000) 105 48%
Pierantozzi et al.12 (2007) 79 36%
Lee et al.13 (2008) 65 53%
Dobbs et al.14 (2012) 51 70%
Tan et al.15 (2015) 102 32%
HP: Helicobacter pylori, PD: Parkinson’s disease.
www.thejcn.com 149
C¸amcı G and Oğuz S
JCN
‘on-time’.
The study of Rahne et al.29 involved 75 patients who had been diagnosed with PD at least 4 years previously, and eval- uated symptom fluctuations by using UPDRS-IV and the 9-items Wearing-Off-Questionnaire scale. HP infection was detected in 20 (27%) patients using the urea breath test, and levodopa doses of PD patients with HP infection were higher.
In HP-positive PD patients enrolled in the study, ‘wearing off’
and sleep disorders were significantly less common. Symp- tom fluctuations also decreased in HP-positive PD patients.
That study showed that HP infection might change the ab- sorption of levodopa in the gastrointestinal tract.
Dobbs et al.30 reported that 21 of 66 PD patients had pre- viously received HP treatment, and that 13 had HP. The urea breath tests performed in that study detected HP positivity in 40 patients. They found that HP eradication improved tremor, rigidity, hypokinesia and walking ability. Other anti- microbial treatments were found to be insufficient for treat- ing HP, and resulted in worsening rigidity and tremor in the patients. That study demonstrated that HP should be eradi- cated by applying proper antibiotic treatment.
Bjarnason et al.31 conducted a randomized, double blind and placebo controlled study to investigate the relationship between HP infection and idiopathic PD. The patients were followed for 1 year to monitor the success of HP eradication.
Those authors concluded that HP infection might cause id- iopathic PD. Stride length and rigidity were found to be worse in HP positive PD patients. Successful HP eradication decreased the symptoms in patients with idiopathic PD, and HP infection was found to affect the absorption of levodopa.
In a randomized, placebo controlled, and parallel group study, Dobbs et al.32 found that the mean stride length was 3 mm (range, -47 to 52 mm) in the placebo group (n=16) and 75 mm (range, 41 to 110 mm) in the control group (n=12, HP eradicated group) (p=0.01). the mean extension ri- gidity was -1×10-3 Nm (range, -141×10-3 to 143×10-3 Nm) in the placebo group and 238×10-3 Nm (range, 115×10-3 to 361×10-3 Nm) in the control group (p=0.01). HP was not eradicated in four patients in whom stride lengths were found to be shorter.
Hashim et al.33 obtained positive results in the urea breath test in 27 (32.9%) of 82 PD patients. UPDRS (p=0.005), with 39-items Parkinson’s Disease Questionnaire (PDQ39) (p<
0.0001) scores significantly worse for HP-positive patients than for HP-negative PD patients. The levodopa ‘onset’ time shortened and the ‘on-time’ increased in the patients follow- ing 14 weeks of HP-eradication treatment, while the UPDRS and PDQ39 scores also improved significantly.
Pierantozzi et al.28 detected fluctuations in levodopa ab- sorption in six HP-positive PD patients but not in HP-nega-
tive patients, and the UPDRS scores of the patients decreased after HP eradication.
Niehues and Hensel26 investigated the in-vitro effect of HP on levodopa, and found that HP caused a significant decrease in the levodopa concentration, and therefore might also be able to change the clinical status of PD patients.
Narożańska et al.34 detected HP positivity in 18 of 37 PD patients, but found no significant difference between HP- positive and HP-negative patients in terms of scores on the UPDRS and Hoehn-Yahr scales.
The present study was part an ongoing study of the effects of HP eradication to PD patients that has a double-blind, randomized, placebo-controlled trial design involving a rela- tively large cohort of patients. The trial started in December 2013 and the results are still not disclosed. The results of that larger study could provide us with more-accurate results.35
CONCLUSION
The prevalence of HP infection is high among PD patients.
Various studies have revealed that HP causes motor fluctua- tions in PD patients by affecting the absorption of levodopa.
Therefore, PD patients should be evaluated for the presence of HP infection and eradication treatment can be applied in cases where HP positivity is detected. The relationship be- tween HP and PD should be further clarified by more-com- prehensive studies in the future.
Conflicts of Interest
The authors have no financial conflicts of interest.
REFERENCES
1. Memiş S. Parkinson hastalığı ve bakım. In: Durna Z, editor. Kronik Hastalıklar ve Bakım. İstanbul: Nobel Tıp Kitabevi, 2011;277.
2. Barnum CJ, Tansey MG. Neuroinflammation and non-motor symp- toms: the dark passenger of Parkinson’s disease? Curr Neurol Neuro- sci Rep 2012;12:350-358.
3. Bu XL, Wang X, Xiang Y, Shen LL, Wang QH, Liu YH, et al. The as- sociation between infectious burden and Parkinson’s disease: a case- control study. Parkinsonism Relat Disord 2015;21:877-881.
4. Tan AH, Mahadeva S, Thalha AM, Gibson PR, Kiew CK, Yeat CM, et al. Small intestinal bacterial overgrowth in Parkinson’s disease.
Parkinsonism Relat Disord 2014;20:535-540.
5. Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clini- cal Excellence. Non-motor symptoms of Parkinson’s disease: diagno- sis and management. Lancet Neurol 2006;5:235-245.
6. Simuni T, Sethi K. Nonmotor manifestations of Parkinson’s disease.
Ann Neurol 2008;64 Suppl 2:S65-S80.
7. Lim SY, Lang AE. The nonmotor symptoms of Parkinson’s disease-- an overview. Mov Disord 2010;25 Suppl 1:S123-S130.
8. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597-1604.
9. Franceschi F, Gasbarrini A. Helicobacter pylori and extragastric dis- eases. Best Pract Res Clin Gastroenterol 2007;21:325-334.
10. Tan HJ, Goh KL. Extragastrointestinal manifestations of Helicobacter
150 J Clin Neurol 2016;12(2):147-150
Parkinson’s Disease and Helicobacter Pylori
JCN
Neuropharmacol 2014;37:91-95.
24. Pfeiffer R. Beyond here be dragons: SIBO in Parkinson’s disease. Mov Disord 2013;28:1764-1765.
25. Lahner E, Annibale B, Delle Fave G. Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther 2009;29:379-386.
26. Niehues M, Hensel A. In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differ- ences in bioavailability? J Pharm Pharmacol 2009;61:1303-1307.
27. Lyte M. Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson’s patients treated for Helicobacter pylori.
Med Hypotheses 2010;74:895-897.
28. Pierantozzi M, Pietroiusti A, Sancesario G, Lunardi G, Fedele E, Gia- comini P, et al. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson’s disease pa- tients. Neurol Sci 2001;22:89-91.
29. Rahne KE, Tagesson C, Nyholm D. Motor fluctuations and Helico- bacter pylori in Parkinson’s disease. J Neurol 2013;260:2974-2980.
30. Dobbs SM, Charlett A, Dobbs RJ, Weller C, Iguodala O, Smee C, et al. Antimicrobial surveillance in idiopathic parkinsonism: indica- tion-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity. Helicobacter 2013;18:187-196.
31. Bjarnason IT, Charlett A, Dobbs RJ, Dobbs SM, Ibrahim MA, Kerwin RW, et al. Role of chronic infection and inflammation in the gastroin- testinal tract in the etiology and pathogenesis of idiopathic parkinson- ism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, place- bo-controlled efficacy study. Helicobacter 2005;10:276-287.
32. Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, et al. Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkin- sonism. Helicobacter 2010;15:279-294.
33. Hashim H, Azmin S, Razlan H, Yahya NW, Tan HJ, Manaf MR, et al.
Eradication of Helicobacter pylori infection improves levodopa ac- tion, clinical symptoms and quality of life in patients with Parkin- son’s disease. PLoS One 2014;9:e112330.
34. Narożańska E, Białecka M, Adamiak-Giera U, Gawrońska-Szklarz B, Sołtan W, Schinwelski M, et al. Pharmacokinetics of levodopa in pa- tients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection. Clin Neuropharmacol 2014;37:96-99.
35. ClinicalTrials.gov (US). Helicobacter pylori eradication in Parkinson’s disease: a double-blind randomised placebo controlled trial [Internet].
Kuala Lumpur: University of Malaya; 2014 [cited 2015 Sep 16]. Avail- able from: https://clinicaltrials.gov/show/NCT02108704.
pylori infection: facts or myth? A critical review. J Dig Dis 2012;13:342- 11. Dobbs RJ, Charlett A, Dobbs SM, Weller C, Peterson DW. Parkin-349.
sonism: differential age-trend in Helicobacter pylori antibody. Ali- ment Pharmacol Ther 2000;14:1199-1205.
12. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, et al. Helicobacter pylori eradication and l-dopa absorption in pa- tients with PD and motor fluctuations. Neurology 2006;66:1824-1829.
13. Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL. Helicobacter pylori infection and motor fluctuations in patients with Parkinson’s disease.
Mov Disord 2008;23:1696-1700.
14. Dobbs RJ, Charlett A, Dobbs SM, Weller C, A Ibrahim MA, Iguodala O, et al. Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. Gut Pathog 2012;4:12.
15. Tan AH, Mahadeva S, Marras C, Thalha AM, Kiew CK, Yeat CM, et al. Helicobacter pylori infection is associated with worse severity of Parkinson’s disease. Parkinsonism Relat Disord 2015;21:221-225.
16. Weller C, Charlett A, Oxlade NL, Dobbs SM, Dobbs RJ, Peterson DW, et al. Role of chronic infection and inflammation in the gastro- intestinal tract in the etiology and pathogenesis of idiopathic parkin- sonism. Part 3: predicted probability and gradients of severity of idio- pathic parkinsonism based on H. pylori antibody profile. Helicobacter 2005;10:288-297.
17. Charlett A, Dobbs RJ, Dobbs SM, Weller C, Brady P, Peterson DW.
Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome. Acta Neurol Scand 1999;99:26-35.
18. Blaecher C, Smet A, Flahou B, Pasmans F, Ducatelle R, Taylor D, et al. Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients. Aliment Phar- macol Ther 2013;38:1347-1353.
19. Dobbs SM, Dobbs RJ, Weller C, Charlett A. Link between Helico- bacter pylori infection and idiopathic parkinsonism. Med Hypotheses 2000;55:93-98.
20. Schulz JD, Hawkes EL, Shaw CA. Cycad toxins, Helicobacter pylori and parkinsonism: cholesterol glucosides as the common denomena- tor. Med Hypotheses 2006;66:1222-1226.
21. Dobbs RJ, Dobbs SM, Weller C, Charlett A, Bjarnason IT, Curry A, et al. Helicobacter hypothesis for idiopathic parkinsonism: before and beyond. Helicobacter 2008;13:309-322.
22. Kountouras J, Zavos C, Polyzos SA, Deretzi G, Vardaka E, Giartza- Taxidou E, et al. Helicobacter pylori infection and Parkinson’s dis- ease: apoptosis as an underlying common contributor. Eur J Neurol 2012;19:e56.
23. Fasano A, Bove F, Gabrielli M, Ragazzoni E, Fortuna S, Tortora A, et al. Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth. Clin
